In a recent study, the use of cabozantinib after progression of renal cell carcinoma (RCC) was assessed.
Forty-five (45) patients continued with treatment with cabozantinib after their disease had progressed, and 44 patients switched to cabozantinib. Nearly 60% of patients had been treated with two or more prior treatments. Of these patients, most (85%) had intermediate–poor risk cancer.
Patients continuing with cabozantinib had a higher response rate to the treatment than before their cancer progressed (46.7% vs 25%) and were more heavily pretreated. Continuing cabozantinib after their cancer had progressed was associated with longer survival compared with changing treatment (average post-progression survival was 16.9 vs 13.2 months).
In this study the researchers observed longer post-progression survival in patients continuing cabozantinib after their cancer had progressed, suggesting that this could be an effective treatment option.